Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain
ConditionHip Osteoarthritis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21-80
SponsorLifeBridge Health
About this trial
Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 21-80 years
Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis
Disqualifiers
Any injections into the target Hip within three months
Current overlying skin infection
Current or previous diagnosis of "chronic pain"
Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
Trial design
Treatments tested in this trial
- Platelet Rich Plasma Joint Injection
- Corticosteroid Injection
Treatment groups
54 Participants
are divided into 2 treatment groupsSponsors and collaborators
LifeBridge Health
Lead sponsor
Hip Society
Collaborator
Source ClinicalTrials.gov